hcit checkup top name
strong momentum look like solid long-term invest opportun
favor risk/reward outlook experienc recent hiccup thu
summari last week mark end first quarter earn season major
healthcar servic healthcar inform technolog hcit coverag univers
often period mark bevi earn releas overlap confer
call thu limit time digest noteworthi event key takeawaysand even
current environ compani sift impact
want turn focu five key name coverag list monitor go forward
via recur quarterli ep recap report hcit
intent report focu five cover name believ
categor show-m stock
also decid take slightli differ approach select name focu
report first quarter manag team incorpor
impact pandem commentari financi outlook thu
thought would use frame select name revisit day three
price perform potenti bounce-back name identifi top pick
potenti bounce-back name believ present best near-term alpha
exhibit begin analysi sever factor cover
pre-covid price valuat base ntm estim
price ntm valuat publish top pick
current price ntm valuat base updat forecast post first-quart
result compani
price chang sinc pre-covid price movement sinc day
three top pick note
gener potenti univers base disconnect valuat
view underli fundament
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
shown exhibit week follow believ strong earn report forward outlook
evol health name recommend top listhav perform opposit end
spectrum sinc outbreak hit market share still
case evol stock rebound nice lowsup sinc april remain
pre-covid price compani report first-quart sale ep beat provid second-quart guidanc
street announc two new strateg partner reiter full year guidanc manag also indic
seen littl impact overal date remain confid achiev full year
compani report record sale first quarter manag note myriad favor pipelin
dynam also believ pandem posit impact digit market spend pharmaceut
manufactur send rep provid offic promot product person could sustain go
forwardanoth key posit compani still stock remain price despit
increas nearli sinc april note
continu favor share pre-covid level also rel
flat trade late sinc april unlik evol manag
withdraw full year guidanc due sales-rel uncertainti relat howev believ impact
rel modest given larg recur revenu model importantli continu believ long-term
growth outlook compani strong
healthcar servic front highlight prior
checkup report well teladoc believ momentum remain strong outbreak
drive near-term use compani servic also view push telehealth solut mainstream
healthcar also view pend acquisit intouch highli favor add anoth leg growth
competit differenti stori
compani report strong first-quart result withdraw guidanc due
impact veterinari end-market state believ industri alreadi experienc v-shape
recoveri discuss weekli vet tracker week-fiv updat v-shape recoveri appear detail
healthcar healthcar impact summarycompani tickerratingpricepric earningsev ebitdaev salespricepric earningsev ebitdaev salespricepric earningsev ebitdaev salesfrom itevol health servicest health healthcar industri daniel cfa assum price assum price assum price factset william blair equiti ntm ntm percent changeprior ntm market performu under-perform william blair
continu see strong long-term port stormi market also continu view anim
health industri favor elect year
compani provid brief recap quarterli develop earn recap guidanc outlook key
takeaway quarter believ one key manag comment earn call etc well
thought take produc alpha gener five name next six month
conclud detail valuat profil compani well updat financi model
checkup report focu follow five stock
steadi goe
show-m stock n/a remov categori prior report place strong
sale came million rise year-over-year organ nice ahead million consensu forecast
adjust ebitda solid well regist millioncompar guidanc million million
importantli view compani pipelin commentari also continu strong manag
highlight expans exist partner includ strong client renew two new
relationshipsa partnership emblemhealth one nation largest nonprofit health insur new york
second partnership unnam region nonprofit health plan medicaid dual-elig exchang
member northeast
overal would character quarter strong start year evol despit difficult macro
detail recap found first look strong first-quart perform guidanc maintain new
manag reiter full-year outlook impli least organ servic growth note
consist initi formal guidanc provid februari conjunct fourth-quart report also
manag preliminari commentari evol present jp morgan confer januari
addit manag reiter outlook ramp profit cash flow throughout year specif
call break-even cash flow back half
lastli perhap importantli compani state full visibl revenu guidanc
point year thu reliant materi new sale cours meet consensu expect
key manag commentari earn call
stage experienc materi neg impact busi remain
well-posit market given mission critic natur servic offer diversifi
custom base cours acknowledg evolv unpreced situat continu
close monitor busi ensur prepar address major issu aris
addit continu make signific progress margin enhanc effort expand
diversifi nation network payer provid partner
importantli across last sever week team respond quickli comprehens support
partner rapidli evolv public health crisi collect work signific posit
co-found ceo director frank william compani may earn call
take view comment underscor inher durabl compani core servic model
organ face materi impact busi thu far despit modest elong sale cycl
case despit complic macro backdrop organ continu full visibl robust sale growth
outlook margin expans throughout
stock reaction share trade rel flat session follow first-quart ep beat share close
compar prior day close next week share trade modestli perhap street
digest manag bullish commentari ndr host us well america healthcar confer
still stock current trade high
outlook alpha base stock reaction post-quart investor clearli focus next major catalyst
evol pend medicaid rfp kentucki believ like investor prefer wait decis
put money work said regardless potenti outcom kentucki believ underli core
busi remain underappreci investor sole focus kentucki
prior decis extend current medicaid contract kentucki end manag
indic anticip double-digit servic growth event passport wasnt renew full year
passport line reiter guidanc compani continu report strong pipelin commentari
particularli driven specialti care manag product traction new partner thu far
well way achiev manag guidanc exist clientswith reflect strongest same-
store growth cycl compani histori
furthermor discuss greater detail recap note follow investor meet manag
takeaway meet manag growth outlook remain strong highli visibl believ
two potenti growth tailwind evol
first short run believ could meaning shift manag live medicaid job loss mount
due given half evol live manag medicaid believ compani
would like net beneficiari transit live away commerci channel evol
second longer term believ pandem could prove support acceler push
toward value-bas care on-going crisi could long-term pipelin implic
includ recent elimin enrol period new medicar aco believ overal
movement value-bas care progress apac
specif note value-bas care design provid incent paid volum recent
weak healthcar volum concomit impact provid financi could actual encourag
particip payment model time view
acknowledg impend medicaid decis creat volatil stock short run continu see
robust long-term growth outlook evol favor macro environ
stock thought risk mention earlier share under-perform last year given headwind
first half growth investor constern regard passport invest still-outstand kentucki manag
medicaid bid share trade roughli time sale forecast view attract risk/reward
level stock given compani uniqu market posit larg grow address market still-robust
minimum believ share abl hold valuat level expand growth reacceler
long-term passport uncertainti abat appreci line organ sale growth go forward thu reiter
outperform rate continu recommend purchas share
risk includ continu volatil surround passport kentucki manag medicaid contract risk client
consolid contract insourc
total sale beat million street target come record million year-over-year adjust ep
front compani regist modest loss loss street target quarterli sale
beat critic view believ name show-m territori investor follow disappoint
third quarter miss report sale period million well million consensu detail
recap found record quarterli sale higher close rate reduc sale cycl also point strong futur
compani provid formal guidanc believ key indic futur perform robust
pipelin commentari provid manag specif manag note close rate increas
histor level sale cycl declin day roughli day present manufactur
look novel market vehicl midst pandem note believ organ may
incur benefit first quarter relat confer travel cancel push market
effort digit channel longer term believ could provid last tailwind robust growth
compani also continu garner traction enterpris platform sale provid recur subscript revenu
stream versu legaci revenu transact base prescript volum compani sign
engag averag contractu valu acv million averag believ
posit develop shift sale stream predict subscription-bas model also
showcas valu proposit broader digit commun platform multipl channel engag
provid patient
key manag comment earn call
regard impact busi provid still use ehr home key
stay seen drop brand e-prescript cours thrill
percent -- increas year-over-year revenu growth perhap importantli seen
close rate increas sale cycl decreas day late
continu receiv posit respons propos enterprise-level engag view
togeth averag annual contract valu million also feel strong
tailwind back term client base client decid hold new launch
due complex cost around prepar part overal strategi design
prevent substanti disrupt medic confer medic liaison live advisori board
disrupt expect drive increas demand digit commun deliv mission-
fda also commit acceler approv new medic indic mani new novel
therapi come market come month year help provid healthi
pipelin new opportun futur
ceo febbo compani may earn call
take comment reinforc compani continu see strong demand solut minim disrupt
relat rather believ one compani coverag univers addit
teladoc could emerg pandem stronger footinga pharmaceut compani increasingli look
leverag digit channel reach patient provid thu believ compani remain rel unaffect
short-term time believ could provid addit tailwind alreadi robust growth outlook
stock reaction follow first-quart report share rose close week
follow report stock continu appreci nice expect momentum remain strong year-
outlook alpha short run believ compani busi well posit growth balanc
due tailwind improv sale pipelin long-term anticip adopt digit
commun provid anoth tailwind alreadi robust growth stori
valuat believ compani continu pivot away transact sale toward recur subscript model
provid greater visibl stickier sale stream believ investor like reward expand
stock thought risk view manag outlin larg growth opportun go forward
momentum extend throughout driven sever factor includ larg grow yet
mostli untap market opportun deliv digit messag solut pharmaceut client cross-sel
opportun novel solut clinic messag patient engag posit network extern
drive favor scale economi margin upsid
therefor maintain outperform rate continu see favor risk/reward opportun
stock present share trade roughli time revenu target
risk includ potenti complex sale cycl given shift enterpris deal concomit impact
could win rate regulatori polit uncertainti lead delay end-market activ patent
expir could lead reduct client spend digit market initi
sale rose year-over-year almost organ million million consensu target
within manag posit prereleas guidanc rang adjust ebitda million line street
target million within manag guid rang compani also end quarter million
 paid member detail recap found result match posit prereleas visit momentum continu
manag provid full year second quarter guidanc well street call sale second
quarter million million versu consensu estim million adjust ebitda
million million compar consensu estim million net loss per share
top street expect loss per share
full year manag expect sale rang million million markedli
consensu estim million adjust ebitda million million versu street million
target net loss per share versu street target neg per share
key manag commentari earn call
play critic role global outbreak seen signific increas
inquiri exist new potenti client client turn us expand servic offer
new popul add new product time need
request new potenti client increas outbreak highlight valu
access comprehens virtual healthcar solut first quarter alon onboard
million new paid member across govern commerci popul anticip
onboard addit million million new member second quarter culmin
strongest first half membership growth compani histori
discuss busi updat call two week ago remark growth across platform
enabl tremend respons part team member physician respond
surg demand rapidli expand capac physician network includ onboard
thousand new provid doubl number licens physician network
invest capac made month march posit us meet increas demand
exist member well new member process onboard
turn visit cross new mileston total visit exceed million first quarter repres
growth nearli compar first quarter particularli noteworthi come
month cross million visit per quarter mark first quarter last year first two
month year strong visit volum acceler significantli throughout march april
shelter-in-plac order began zero-dollar copay implement brick-and-mortar facil close
ceo jason gorev compani april earn call
take comment emphas novel coronaviru well thing like heighten flu season boost
util also drive increas interest new exist teladoc client improv compani sell
abil increas interest adopt serv continu boost util next year growth
util rise nonlinear fashion cohort matur product offer
new memberswho adopt telehealth respons eas conveni
telehealth like continu util offer futur thu increas awar util driven
actual serv pull forward telehealth adopt speed process telehealth util becom
ubiquit healthcar system view
stock reaction share declin day follow compani earn report
sinc report share rebound rise though still roughli flat sinc print
outlook alpha posit commentari surround visit volum result coronaviru could propel share
higher given highlight sign potenti second-wav fall could propel share higher
account manag guidanc success result onboard unit
live well inform surround telehealth accept govern payor new contract
provid servic medicar advantag plan would prove posit catalyst share view
stock thought risk continu view teladoc solid small-cap growth invest believ telehealth
industri precipic materi growth come yearsspur part massiv recent adopt help
deal pandem across globe also believ follow acquisit best doctor
advanc medic not-yet-clos acquisit intouch teladoc increas competit
differentiationa organ match compani intern scale scope offer
across continuum care number distribut channel teladoc target
share current trade time sale targetan expens multipl appropri one view
given compani robust growth rate larg market potenti accordingli continu favor teladoc share
long term reiter outperform rate would activ purchas pullback
risk includ slowdown compani contract win provid telehealth servic health plan provid lack
growth telehealth util rate emerg competit telehealth provid well novel entrant
includ outperform zoom video commun zm outperform risk
surround close intouch health acquisit
steadi goe
report solid first quarter result larg line manag posit prereleas
earli april specif file april manag indic expect first-quart revenu fall
million million ahead previous issu first-quart guidanc rang million
million respect adjust loss interest tax depreci amort manag indic
expect beat midpoint prior guidanc loss million million
look actual quarterli result sale came high end prereleas rang regist million
year-over-year street consensu head print million furthermor adjust loss
interest tax depreci amort also regist line compani prereleas commentari come
million compar million loss consensu forecast segment-level basi technolog revenu rose
year-over-year million profession servic revenu increas million
detail recap found first-quart result top april prereleas continu compel long-term
conjunct aforement april prereleas commentari manag withdrew full-year outlook
unsurprisingli view light coronaviru pandem prior guidanc issu conjunct
fourth-quart ep report call revenu million million roughli organ growth
similar revenue-retent rate well addit do clientsalso consist last
manag provid second-quart guidanc call revenu million million
adjust loss interest tax depreci amort million million compar
respect street target million million
compani indic like feel larger impact profession servic sale stream may see
elev level churn price discount near term manag also note somewhat lower visibl
net-new technolog subscript custom year health system execut continu focu deal
pandem versu key healthcar technolog invest still believ larg recur sale model strong long-
term client valu proposit foster strong organ growth beyond
key manag comment earn call
would share think event recent histori galvan awar
import data analyt healthcar provid level also
state nation healthcar infrastructur level believ reach inflect point
healthcar deliveri model like serv medium long-term tailwind industri
adopt data analyt
ceo burton compani may earn call
take quot reinforc potenti pandem serv tailwind futur growth acceler
rate adopt novel data platform analyt capabl compani continu primarili displac
homegrown data platform market believ signific runway health system invest
professional-grad data analyt solut time
stock reaction follow quarterli result share fell follow trade session
close price stock sinc recov share current trade still well
high investor continu focu near-term disrupt sale cycl continu see
robust long-term growth outlook compani
outlook alpha point believ investor primarili focus given impact limit visibl
given on-going pandem organ long sale cycl could impact growth
pipelin opportun slower convert book believ increment commentari next two quarter
especi relat sale pipelinewil therefor critic provid comfort investor repres
anoth year strong organ growth
long term previous mention believ pandem like produc acceler digit
healthcar support need data analyt infrastructur encourag view manag note
pandem led exist custom leverag exist technolog ever meaning
signific way respond
stock thought risk estim share current trade approxim time estim fiscal
revenu premium peer hcit competitor warrant view given compani uniqu invest attribut
discuss much detail initi coverag report leverag data catalyst improv
healthcar initi coverag outperform rate august
would anticip materi multipl expans believ compani maintain current multipl
perhap experi modest expans march toward adjust ebitda break-even thu least appreci
line strong sale growth maintain outperform rate continu view core long-term healthcar
risk includ gener inertia healthcar organ may slow adopt novel technolog solut long sale
cycleespeci given outbreak competit threat electron health record ehr vendor
activ enter compani marketplac provid consolid could drive price pressur time
stead goe
sale rose year-over-year organ growth recur companion anim group diagnost busi
million million consensu target adjust ep full better
consensu forecast year-over-year compar constant-curr basi thing consid idexx
also solid quarter instrument placement catalyst analyz place quarter bulk new
competit account detail recap found solid result despit end-market nois impact
client base long-term outlook remain strong
theme across servic univers manag withdrew guidanc result continu uncertainti
surround pandem impact veterinari end-market
key manag comment earn call
track data impact time insight emerg one insight
veterinari practic sustain oper essenti servic initi high social distanc
period posit market strong recoveri track number custom
chemistri run declin prior-year level peak pressur period earli
april return prior-year level last two week
activ custom track metric also rebound strongli europ saw meaning
reduct activ clinic level earlier expans lockdown region like itali spain
see structur market strength asia pacif region well
second insight effect diagnost test level appear heavili influenc stage
develop case manag associ stage stay-at-hom social distanc
procedur signific variat level declin diagnost test volum region region
higher rel case expand lockdown polici experienc much signific
clinic visit diagnost test volum declin exampl clinic visit northeast declin
approxim late march mid-april southern region declin approxim
period recent data southern region show year-on-year declin less
intern near-term pressur lab access volum region like germani much
moder compar market extend lockdown condit like unit kingdom canada asia
pacif market also see moder impact region farther along term manag
pandem effect includ recent solid growth vetlab chemistri run market like australia
less restrict social distanc control dynam continu monitor challeng
project overal appear region move past peak level case adjust stay-at-
home social distanc procedur near-term pressur clinic visit activ relat diagnost
ceo jon mazelski compani april earn call
take comment highlight idexx abil benefit shape v-shape recoveri vet clinic
volum social distanc measur subsid manag highlight veterinari clinic remain open given
essenti natur simpli shift volum away well visit focus essenti emerg
visit demonstr variabl clinic geographi clinic area affect viru
thu strict social distanc measur show larger declin diagnost util one would expect
note most-rec weekli note health veterinari market weekli vet tracker week-fiv updat v-
shape recoveri appear clear data vet clinic revenu invoic bolster idea v-shape
recoveri vet clinic volum vet clinic revenu roughli week may versu period last
year signific turnaround low seen week march sinc began collect data first week
march revenu declin almost
invoic proxi volum also reach posit territori year-over-year basi
recent week data compar declin almost week march
stock reaction solid quarter share rose day follow compani
earn report sinc report share continu appreci rise addit
outlook alpha next major data point like aris report second quarter result
summer said key area alpha gener like maintain current multipl appreci line
solid earn growth view sinc report first quarter result view posit share
trade settl around time ep estim though admit expens multipl
share trade averag time ep past three year
said given rel recession-resist model govern reimburs risk view safe hold
elect year given recent coronaviru outbreak potenti impact could area
stock thought risk continu believ long-term invest merit remain compel high
entry-barri space lead instal base larg innov lead competitor profit razor/razorblad busi
model solid geograph product divers govern reimbursement/elect risk particularli attract
characterist view head elect concomit healthcar polici debat solid balanc sheet
cash flow superior return invest capit strong manag team
stock current trade roughli time ep target time ebitda estim
lofti multipl believ durabl busi franchis warrant premium valuat note current
multipl larg line stock three-year averag thu reiter outperform rate continu view
organ durabl busi franchis warrant long-term invest core growth portfolio
risk includ slowdown growth result lower-than-expect equip placement reduc diagnost usag
increas competit diagnost space broader slowdown pet-own spend slower-than-expect
adopt diagnost outsid unit state well pressur idexx end-market result
provid exhibit display histor valuat trend detail valuat analysi across sever key trade
multipl summari financi model compani highlight note
detail copi earn model pleas contact william blair sale repres
sourc factset compani report william blair estimatesevol healthev ntm salesavgsourc factset compani report william blair estimatesoptimizerx corporationev ntm mo average william blair
sourc factset compani report william blair estimatesteladoc healthev ntm avgsourc factset compani report william blair estimateshealth catalystev ntm salesavg
sourc factset compani report william blair estimatesidexx laboratoriespric ntm average william blair
evol inc rate outperformoper result summari million except per-shar statementrevenuetransform platform total servic plan less inter-company consolid net revenu servic medic total cost revenu gross profit sell gener administr adjust ebitda depreci adjust oper incom adjust net incom adjust ep econom fulli dilut margin analysi gross margin servic gross gener administr adjust ebitda adjust oper incom adjust tax adjust net margin net year-over-year platform total organ revenu gross profit adjust ebitda adjust oper incom adjust net incom adjust ep net exclud stock compens expens special item base econom fulli dilut share countryan daniel cfa consult import disclosur link william blair
